Rockefeller Capital Management
LXRX icon

Rockefeller Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Rockefeller Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$720 Sell
300
-35
-10% -$68 ﹤0.01% 4560
2026
Q1 		$523 Hold
335
– – ﹤0.01% 4557
2025
Q4 		$385 Hold
335
– – ﹤0.01% 4551
2025
Q3 		$452 Buy
+335
New +$380 ﹤0.01% 4280
2023
Q1 		– Sell
-3,000
Closed -$5K – 3090
2022
Q4 		$5K Buy
+3,000
New +$6.38K ﹤0.01% 3331
2021
Q1 		– Sell
-182
Closed – – 3335
2020
Q4 		$0 Buy
+182
New +$347 ﹤0.01% 2948

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Rockefeller Capital Management's LXRX Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Lexicon Pharmaceuticals (LXRX) stake by 10% in Q2 2026, selling an estimated $68 and leaving 300 shares worth $720. The position accounts for ﹤0.01% of the portfolio, ranked #4560.

Rockefeller Capital Management first reported a position in LXRX in Q4 2020 and has held it in 6 quarters since. The position peaked at $5K in Q4 2022. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Rockefeller Capital Management held 300 shares of Lexicon Pharmaceuticals worth $720 as of Q2 2026.
  • Rockefeller Capital Management sold 35 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $68.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4560 holding.
  • Rockefeller Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2020 and has held it in 6 quarters since.
  • Rockefeller Capital Management's Lexicon Pharmaceuticals position peaked at $5K in Q4 2022.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.